Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Time to progression
Progression-free survival, overall response rate, overall survival, time to first response, duration of response, CR rate, and patient reported outcomes as assessed using the EORTC QLQ-C30, FACIT-F and EQ-5D instruments.
18 Years and older (Adult, Senior)
May 20, 2005
March 26, 2009
Investigative Clinical Research of Indiana, LLC Indianapolis, Indiana, United States
† Study has passed its completion date and status has not been verified in more than two years.